Published December 27, 2012 by PR Web
St. Louis, MO (PRWEB) December 27, 2012
Pradaxa lawsuits have been consolidated into a Multi-District Litigation being heard in the U.S. District Court, Southern District of Illinois. The Pradaxa MDL has been named Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation. The last Pradaxa MDL meeting occurred on Thursday, December 13, 2012, where Plaintiffs’ representatives as well as the Defendants’ legal counsel convened for a Status Conference.
The MDL No. 2385 is presided over by Chief Judge David R. Herndon in East St. Louis, Illinois. The MDL is currently in the pre-trial discovery phase.
As outlined in the court’s minutes, both sides have been working to approve the First and Second Sets of Discovery gathered by the Plaintiffs legal representatives. Though the two side came to a written agreement on the Second Set of Discovery, in regards to the First, the Plaintiffs’ legal representatives have been working “to resolve pending disputes.”
According to the Pradaxa MDL 2835 Status Conference minutes from December 13, the Plaintiffs’ First Set of Discovery has resulted in a number of unsettled disagreements between the Plaintiffs Lead Counsel and Boehringer Ingelheim Pharmaceuticals, Inc. As court documents detail, Boehringer Ingelheim has objections with regard to the Plaintiffs Lead Counsel’s First Set of Discovery.
As a result of the yet unresolved issues with the First Set of Discovery, Boehringer Ingelheim is filing a protective order, and plans to do so by December 21, 2012. In response to the protective order and in an effort to acquire vital evidence and documents, the Plaintiffs Lead Counsel plans to file a responsive pleading early next year.
Currently, over 170 plaintiffs have a case that has been consolidated into MDL No. 2385. These plaintiffs claim that the ingestion of Pradaxa led to serious Pradaxa-related injuries including excessive bleeding, uncontrollable bleeding, and fatal bleed-outs. Furthermore, these Pradaxa lawsuits claim that Boehringer Ingelheim neglected to warn healthcare providers and patients about the risks of using Pradaxa.
In addition, plaintiffs accuse Boehringer Ingelheim of further negligence in light of Pradaxa’s release onto the market without the simultaneous release of a reversal agent which is vital in treating excessive bleeding. Unlike warfarin which is counteracted by Vitamin K in excessive bleeding episodes, Pradaxa has no known panacea or reversal agent to control excessive bleeding.
Attorneys at Carey Danis & Lowe are currently seeking claims from individuals who have experienced a Pradaxa injury, including those listed above, such as excessive and uncontrollable bleeding events. For more information about filing a Pradaxa lawsuit, contact a defective drug lawyer at Carey Danis & Lowe at 800-721-2519.References: Pharmaceutical litigation, Pradaxa